Core Insights - The company reported strong financial performance for Q1-Q3 2025, with revenue of 613 million and a year-on-year growth of 32.26%, and a net profit of 132 million, up 58.61% year-on-year [1] - The company plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its international presence and expand its global financing and acquisition channels [3] - The company focuses on recombinant proteins and GMP-grade raw materials, which are crucial for the development and production of CGT innovative drugs [4] Financial Performance - For Q3 2025, the company achieved revenue of 226 million, a year-on-year increase of 37.50% and a quarter-on-quarter increase of 12.32% [1] - The net profit for Q3 2025 was 48.62 million, reflecting an 81.46% year-on-year growth and a 12.49% quarter-on-quarter growth [1] - The company’s operating expenses have been effectively managed, with a decrease in sales, management, and R&D expense ratios compared to the previous year [2] Strategic Initiatives - The company is enhancing its operational efficiency through cost control and improved management practices, leading to a reduction in expense ratios across various categories [2] - The establishment of overseas subsidiaries and logistics centers is part of the strategy to deepen international operations and ensure comprehensive market coverage [3] - The company aims to strengthen its global supply chain capabilities by building overseas production bases and increasing R&D investments [3] Market Outlook - Revenue forecasts for 2025 and 2026 have been revised upwards to 845 million and 1.041 billion, respectively, with net profits expected to reach 208 million and 233 million [5] - The company anticipates significant revenue growth, projecting 1.288 billion in revenue and 296 million in net profit for 2027 [5]